868136-51-0Relevant academic research and scientific papers
Development of N-2,4-pyrimidine-N-phenyl-N′-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-α) synthesis. Part 1
Brugel, Todd A.,Maier, Jennifer A.,Clark, Michael P.,Sabat, Mark,Golebiowski, Adam,Bookland, Roger G.,Laufersweiler, Matthew J.,Laughlin, Steven K.,VanRens, John C.,De, Biswanath,Hsieh, Lily C.,Mekel, Marlene J.,Janusz, Michael J.
, p. 3510 - 3513 (2007/10/03)
A new class of tumor necrosis factor alpha (TNF-α) synthesis inhibitors based on an N-2,4-pyrimidine-N-phenyl-N′-phenyl urea scaffold is described. Many of these compounds showed low-nanomolar activity against lipopolysaccharide stimulated TNF-α productio
Development of N-2,4-pyrimidine-N-phenyl-N′-alkyl ureas as orally active inhibitors of tumor necrosis factor alpha (TNF-α) synthesis. Part 2
Maier, Jennifer A.,Brugel, Todd A.,Clark, Michael P.,Sabat, Mark,Golebiowski, Adam,Bookland, Roger G.,Laufersweiler, Matthew J.,Laughlin, Steven K.,VanRens, John C.,De, Biswanath,Hsieh, Lily C.,Brown, Kimberly K.,Juergens, Karen,Walter, Richard L.,Janusz, Michael J.
, p. 3514 - 3518 (2008/09/20)
A new class of tumor necrosis factor alpha (TNF-α) synthesis inhibitors based on a N-2,4-pyrimidine-N-phenyl-N′-alkyl urea scaffold is described. Many of these compounds showed low-nanomolar activity against lipopolysaccharide stimulated TNF-α production.
Tri-substituted ureas as cytokine inhibitors
-
Page/Page column 7, (2010/02/14)
The present invention relates to 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to c
